"2013 Sales A$15.9m EBITDA -$91.2m ___________ EPS -5.34c
2014 Sales A$340m EBITDA $75.4m NPAT $26.3m EPS 1.34c
2015 Sales A$594m EBITDA $235m NPAT $190.2m EPS 9.70c PE 4.2
2016 Sales A$808m EBITDA $424m NPAT $220.6m EPS 11.25c PE 3.6
2017 Sales A$729m EBITDA $514m "
All of these so-called estimates are purely conjectural.
because this analysis has based on the higher RE price, lower cost basis.
when RE rice will rise? unknown;
When costs can reduce? unknown.
Need to waiting for the macro, waiting for the company's hard-data.
- Forums
- ASX - By Stock
- LYC
- assistance regarding current basket price
assistance regarding current basket price, page-20
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LYC (ASX) to my watchlist
|
|||||
Last
$6.31 |
Change
-0.045(0.71%) |
Mkt cap ! $5.893B |
Open | High | Low | Value | Volume |
$6.34 | $6.35 | $6.29 | $2.301M | 364.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
48 | 20259 | $6.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.31 | 6747 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
35 | 17925 | 6.300 |
26 | 35968 | 6.290 |
13 | 19798 | 6.280 |
9 | 34917 | 6.270 |
4 | 5795 | 6.260 |
Price($) | Vol. | No. |
---|---|---|
6.310 | 8587 | 23 |
6.320 | 18058 | 25 |
6.330 | 29198 | 15 |
6.340 | 22862 | 11 |
6.350 | 30115 | 12 |
Last trade - 11.01am 16/07/2024 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online